TIDMSN.
RNS Number : 2162Q
Smith & Nephew Plc
17 February 2023
Smith+Nephew announces Rupert Soames as Chair Designate
17 February 2023
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology
company (the Company), is pleased to announce that Rupert Soames
OBE will succeed Roberto Quarta as Chair of the Company. Mr Quarta
has reached the end of his tenure and will retire as Chair and
Non-Executive Director in 2023.
Mr Soames will be appointed as an Independent Non-Executive
Director at the Company's Annual General Meeting on 26 April 2023,
subject to shareholder approval, and will succeed Mr Quarta as
Chair with effect from 15 September 2023. Mr Quarta has agreed to
continue as Chair to ensure a smooth transition and will put
himself forward for re-election as a Non-Executive Director on 26
April 2023 on this basis.
Mr Soames has extensive global leadership experience in both
executive and non-executive roles. Most recently he served as Chief
Executive Officer of Serco Group plc, the global outsourced
services provider, between 2014 and 2022 where he led the
successful turnaround. He was Chief Executive of Aggreko plc, the
support services company (2003-2014) and also served as a
Non-Executive Independent Director at both DS Smith, the
sustainable packaging business (2019-2022) and support services
company Electrocomponents plc (2007-2016) (now RS Group). On
joining the Board, Mr Soames will be appointed to the Nomination
& Governance Committee and the Remuneration Committee.
Marc Owen, Senior Independent Director, who along with the
Nomination & Governance Committee led the Chair search process,
commented:
"The Board conducted an extensive search for a new Chair and we
are delighted to welcome Rupert to the Board. We believe that
Rupert's extensive track record of value creation in global
companies and deep understanding of corporate governance will help
Deepak Nath and his team deliver on their existing plans to grow
the business and to improve its operational performance . I would
like to thank Roberto for his unwavering commitment and support to
the Board and for his contribution and service to the Company
during his tenure."
Rupert Soames said:
"Smith+Nephew is a leader in the medical technology sector with
a 167-year history of supporting patients to return to health. I am
honoured to be the next Chair of the Board, and look forward to
working with Deepak, the Smith+Nephew organisation and the Board to
deliver on Smith+Nephew's great potential."
No further disclosure obligations arise under paragraphs (1) to
(6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in
respect of this appointment.
Enquiries
Investors / Analysts
Andrew Swift
Smith+Nephew +44 (0) 1923 477433
Media
Charles Reynolds
Smith+Nephew +44 (0) 1923 477314
Susan Gilchrist / Ayesha Bharmal
Brunswick +44 (0) 20 7404 5959
About Smith+Nephew
Smith+Nephew is a portfolio medical technology company that
exists to restore people's bodies and their self-belief by using
technology to take the limits off living. We call this purpose
'Life Unlimited'. Our 18,000 employees deliver this mission every
day, making a difference to patients' lives through the excellence
of our product portfolio, and the invention and application of new
technologies across our three global franchises of Orthopaedics,
Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.2 billion in 2021.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on Twitter ,
LinkedIn , Instagram or Facebook .
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of COVID, such as the depth and longevity of
its impact, government actions and other restrictive measures taken
in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
COVID; economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers (including, without limitation, as a result of COVID);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers
(including, without limitation, as a result of COVID); competition
for qualified personnel; strategic actions, including acquisitions
and dispositions, our success in performing due diligence, valuing
and integrating acquired businesses; disruption that may result
from transactions or other changes we make in our business plans or
organisation to adapt to market developments; and numerous other
matters that affect us or our markets, including those of a
political, economic, business, competitive or reputational nature.
Please refer to the documents that Smith+Nephew has filed with the
U.S. Securities and Exchange Commission under the U.S. Securities
Exchange Act of 1934, as amended, including Smith+Nephew's most
recent annual report on Form 20-F, for a discussion of certain of
these factors. Any forward-looking statement is based on
information available to Smith+Nephew as of the date of the
statement. All written or oral forward-looking statements
attributable to Smith+Nephew are qualified by this caution.
Smith+Nephew does not undertake any obligation to update or revise
any forward-looking statement to reflect any change in
circumstances or in Smith+Nephew's expectations.
Trademark of Smith+Nephew. Certain marks registered in US Patent
and Trademark Office.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABIGDDXSBDGXL
(END) Dow Jones Newswires
February 17, 2023 02:00 ET (07:00 GMT)
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From Feb 2024 to Mar 2024
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From Mar 2023 to Mar 2024